137 related articles for article (PubMed ID: 38677725)
21. The expression of MYC is strongly dependent on the circular PVT1 expression in pure Gleason pattern 4 of prostatic cancer.
Umemori M; Kurata M; Yamamoto A; Yamamoto K; Ishibashi S; Ikeda M; Tashiro K; Kimura T; Sato S; Takahashi H; Kitagawa M
Med Mol Morphol; 2020 Sep; 53(3):156-167. PubMed ID: 31932969
[TBL] [Abstract][Full Text] [Related]
22. Long Noncoding RNA
Handa H; Honma K; Oda T; Kobayashi N; Kuroda Y; Kimura-Masuda K; Watanabe S; Ishihara R; Murakami Y; Masuda Y; Tahara KI; Takei H; Kasamatsu T; Saitoh T; Murakami H
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992461
[TBL] [Abstract][Full Text] [Related]
23. Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
Nonomiya Y; Noguchi K; Katayama K; Sugimoto Y
Biochem Biophys Res Commun; 2019 Mar; 510(4):501-507. PubMed ID: 30737031
[TBL] [Abstract][Full Text] [Related]
24. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
25. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
Saravi S; Alizzi Z; Tosi S; Hall M; Karteris E
Cells; 2021 Sep; 10(9):. PubMed ID: 34572083
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia.
Zeng C; Yu X; Lai J; Yang L; Chen S; Li Y
J Hematol Oncol; 2015 Nov; 8():126. PubMed ID: 26545364
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
29. circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in small cell lung cancer.
Tolomeo D; Traversa D; Venuto S; Ebbesen KK; García Rodríguez JL; Tamma G; Ranieri M; Simonetti G; Ghetti M; Paganelli M; Visci G; Liso A; Kok K; Muscarella LA; Fabrizio FP; Frassanito MA; Lamanuzzi A; Saltarella I; Solimando AG; Fatica A; Ianniello Z; Marsano RM; Palazzo A; Azzariti A; Longo V; Tommasi S; Galetta D; Catino A; Zito A; Mazza T; Napoli A; Martinelli G; Kjems J; Kristensen LS; Vacca A; Storlazzi CT
Genes Chromosomes Cancer; 2023 Jul; 62(7):377-391. PubMed ID: 36562080
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of the c-MYC oncogene and adjacent long noncoding RNAs PVT1 and CCAT1 in esophageal squamous cell carcinoma.
Roohinejad Z; Bahramian S; Shamsabadi FT; Sahebi R; Amini A; Sabour D; Shafiee M
BMC Cancer; 2023 Jan; 23(1):34. PubMed ID: 36624401
[TBL] [Abstract][Full Text] [Related]
31. MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer.
Sarver AL; Murray CD; Temiz NA; Tseng YY; Bagchi A
Cell Cycle; 2016; 15(7):881-5. PubMed ID: 26889781
[TBL] [Abstract][Full Text] [Related]
32. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
33.
Zamani M; Foroughmand AM; Hajjari MR; Bakhshinejad B; Johnson R; Galehdari H
Front Oncol; 2022; 12():954634. PubMed ID: 36052265
[TBL] [Abstract][Full Text] [Related]
34. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
35. Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin.
Ghetti M; Vannini I; Storlazzi CT; Martinelli G; Simonetti G
Mol Cancer; 2020 Mar; 19(1):69. PubMed ID: 32228602
[TBL] [Abstract][Full Text] [Related]
36. The identification of microRNAs in a genomically unstable region of human chromosome 8q24.
Huppi K; Volfovsky N; Runfola T; Jones TL; Mackiewicz M; Martin SE; Mushinski JF; Stephens R; Caplen NJ
Mol Cancer Res; 2008 Feb; 6(2):212-21. PubMed ID: 18314482
[TBL] [Abstract][Full Text] [Related]
37. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
38. The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer.
Shigeyasu K; Toden S; Ozawa T; Matsuyama T; Nagasaka T; Ishikawa T; Sahoo D; Ghosh P; Uetake H; Fujiwara T; Goel A
Mol Cancer; 2020 Nov; 19(1):155. PubMed ID: 33148262
[TBL] [Abstract][Full Text] [Related]
39. C-Myc-activated long non-coding RNA PVT1 enhances the proliferation of cervical cancer cells by sponging miR-486-3p.
Wang C; Zou H; Chen A; Yang H; Yu X; Yu X; Wang Y
J Biochem; 2020 Jun; 167(6):565-575. PubMed ID: 31943014
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Zhang R; Wang T; Lin J
Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
